GLP-1 Mystery: Why Weight Loss Jabs Don't Work For All

GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, have transformed obesity treatment, yet a notable percentage of individuals find them largely ineffective.

Mercedes, a patient in Canada, has tried multiple GLP-1 drugs over several years with no success, experiencing profound disappointment and self-esteem issues alongside significant financial burdens.

Experts like Professor Alexander Miras acknowledge that drug efficacy is not patient-dependent; if hunger and food intake aren't reduced, the medication won't work. Mercedes reported overwhelming cravings despite lifestyle changes, losing weight only through extreme personal effort, not the medication.

Other patients, such as Yury K from Canada and Lucille from Luxembourg, share similar experiences of minimal or no weight loss despite consistent medication use and healthy habits, alongside reported side effects and high costs.

Research is exploring various factors for this lack of response. While age, sex, type 2 diabetes presence, and ancestry (with European ancestry showing greater efficacy than African American) play roles, genetics are increasingly implicated. A study by 23andMe identified a genetic variant affecting drug receptors, and ongoing research by Adelaide University investigates enzyme modifications that might cause GLP-1 resistance.

Hormonal influences, particularly estrogen levels and menopausal hormone replacement therapy, are also being studied for their impact on GLP-1 response.

While predicting individual responses remains challenging, alternative treatments like non-GLP-1 drugs (e.g., Mysimba) and bariatric surgery offer hope for those who do not benefit from current GLP-1 therapies. Experts emphasize that non-response is not a personal failing but a matter of biological variability.